OmerosOMER
About: Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Employees: 202
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
182% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 11
164% more capital invested
Capital invested by funds: $99.3M [Q3] → $262M (+$163M) [Q4]
92% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 26
19% more funds holding
Funds holding: 108 [Q3] → 128 (+20) [Q4]
2.64% more ownership
Funds ownership: 43.19% [Q3] → 45.83% (+2.64%) [Q4]
9% more call options, than puts
Call options by funds: $12.6M | Put options by funds: $11.6M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
D. Boral Capital Jason Kolbert 28% 1-year accuracy 107 / 376 met price target | 390%upside $36 | Buy Maintained | 11 Apr 2025 |
Financial journalist opinion
Based on 4 articles about OMER published over the past 30 days









